510(k) device
Spectra Optia Apheresis System
Caridianbct, Inc.. · Separator, Automated, Blood Cell And Plasma, Therapeutic (LKN, Unclassified) · First FDA decision Jan 20, 2012, newest Jan 20, 2012Anemia, clotting and blood disorders
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
11
Naming "Spectra Optia Apheresis"
MAUDE reports
17
Brand "Spectra Optia Apheresis", since 2015
PubMed studies
58
Mentioning "Spectra Optia Apheresis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Spectra Optia Apheresis System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K113480 · Decided Jan 20, 2012 · 58 days after receipt
Device type: Separator, Automated, Blood Cell And Plasma, Therapeutic (LKN) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Spectra Optia Apheresis", any status and sponsor, newest update first.
University of ChicagoAcademic, hospital or other
NCT07756242 · 0 participants · Start Nov 2026 · Primary completion Nov 2027
Device: Spectra Optia Apheresis System · For: Immune-related Adverse Event
Sites: Chicago, Illinois
Marker Therapeutics AGNot on our public-company list
NCT04358003 · 107 participants · Start May 20, 2020 · Primary completion Nov 26, 2021
Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) · For: Respiratory Failure; ARDS
Sites: Little Rock, Arkansas; Albuquerque, New Mexico; Portland, Oregon · 7 sites in all
Terumo BCTPublic (4543.T)
NCT02302365 · 43 participants · Start Apr 2014 · Primary completion Jul 2017
Device: Spectra Optia® Apheresis System · For: Leukocytosis
Sites: Leuven, Belgium; Frankfurt am Main, Germany; Budapest, Hungary
8 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Spectra Optia Apheresis", and for the whole product code for context.
This brand
17 reports: 9 malfunction, 7 injury, 1 death
Whole product code LKN
1,471 reports: 891 malfunction, 496 injury, 79 death
Newest reports for this brand
1722028-2025-00090 · Received Apr 17, 2025 · Event dated Jan 30, 2025
Device type: Separator, Automated, Blood Cell And Plasma, Therapeutic (LKN)
Device problem as coded: Adverse Event Without Identified Device or Use Problem; Insufficient Device Problem Information
Patient problem as coded: Hypersensitivity/Allergic reaction; Nausea; Vomiting; Convulsion/Seizure; Paresthesia; Unspecified Gastrointestinal Problem
1722028-2025-00058 · Received Mar 13, 2025 · Event dated Jan 1, 2025
Device type: Separator, Automated, Blood Cell And Plasma, Therapeutic (LKN)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Thrombosis/Thrombus
- SPECTRA OPTIA APHERESIS SYSTEMMalfunction
1722028-2024-00552 · Received Dec 12, 2024 · Event dated Nov 21, 2024
Device type: Separator, Automated, Blood Cell And Plasma, Therapeutic (LKN)
Device problem as coded: Adverse Event Without Identified Device or Use Problem; Insufficient Device Problem Information
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Spectra Optia Apheresis"[tiab]. The summary above synthesizes these.
- A pilot study on impact of use of medium molecular weight hydroxyethyl starch in granulocyte apheresis using Spectra Optia.
Mandal S, Naim F, Kumar R, et al. · Transfus Apher Sci · 2022Observational Study
- Real-World Safety Data From the World Apheresis Association Registry for the Spectra Optia Apheresis System.
Haubner A, Mendoza S, Vrielink H, et al. · J Clin Apher · 2025
- Safety and performance of the Spectra Optia apheresis system for white blood cell depletion in patients with elevated white blood cell counts.
Lopert P, Abdelrahman S, Graybill CA, et al. · J Clin Apher · 2023
- Correction: Impact of custom prime on the PBSC collection efficiency and procedure outcome on Spectra Optia apheresis device by using the CMNC program in low-weight pediatric oncology patients. A single-center experience.
Milojkovik A, Cukjati M, Jazbec J, et al. · Bone Marrow Transplant · 2023Published Erratum
- The safety and performance of the Spectra Optia apheresis system platelet depletion protocol in patients with elevated platelet counts.
Lopert P, Abdelrahman S, Graybill CA, et al. · J Clin Apher · 2022
- Retrospective comparison between COBE SPECTRA and SPECTRA OPTIA apheresis systems for hematopoietic progenitor cells collection for autologous and allogeneic transplantation in a single center.
López-Pereira P, Sola Aparicio E, Vicuña Andrés I, et al. · J Clin Apher · 2020Comparative Study
- Successful Stem Cell Apheresis Using Spectra Optia in a 6ߙkg Child With Atypical Teratoid/Rhabdoid Tumor.
Brust P, Schubert C, Blohm M, et al. · J Pediatr Hematol Oncol · 2020Case Reports
- Spectra Optia granulocyte apheresis collections result in higher collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial.
Cancelas JA, Padmanabhan A, Le T, et al. · Transfusion · 2015Comparative Study, Multicenter Study
- Therapeutic plasma exchange for neonatal hepatic failure.
Sever A, Stein J, Kalo A, et al. · Transfus Apher Sci · 2023Case Reports
- Evaluation of the Spectra Optia apheresis system for mononuclear cell (MNC) collection in G-CSF mobilized and nonmobilized healthy donors: results of a multicenter study.
Karafin MS, Graminske S, Erickson P, et al. · J Clin Apher · 2014Multicenter Study, Research Support, Non-U.S. Gov't
- A Case Report of Therapeutic Plasma Exchange in Hypertriglyceridemia-Induced Pancreatitis.
Behera D, Mallhi RS, Philip J, et al. · Indian J Hematol Blood Transfus · 2024
- Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers.
Azar N, Chao NJ, Cliquennois M, et al. · Transfus Apher Sci · 2025
Other devices of this type
Also filed under product code LKN.
- Prosorba ColumnFresenius Hemocare, Inc. · PMA 2004
- Prosorba Protein a Immunoadsorption ColumnFresenius Hemocare, Inc. · PMA 2005
- Spectra Optia Apheresis SystemTerumobct, Inc. · 510(k) 2019
- Amicus Separator System/ Amicus Seperator SystemFenwal, Inc. · 510(k) 2014
- AMICUS Separator SystemFresenius Kabi AG · 510(k) 2019
- AMICUS Separator SystemFresenius Kabi USA,Llc · 510(k) 2018
- Spectra Optia Apheresis SystemTerumo Bct · 510(k) 2015
- Spectra Optia R Apheresis SystemCaridianbct, Inc.. · 510(k) 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.